Faecal microbiota transplantation: Key points to consider

Bourlioux, P.

doi:10.1016/j.pharma.2015.02.001

Cited by 9 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fecal microbiota transplantation (FMT) was used as an interventional method in patients with recurrent diarrhea when antibiotics fail (183). There is a debate between scientists on its application mainly based in ethical issues and safety.…”

Section: Therapeutic Approachesmentioning

confidence: 99%

“…There is a debate between scientists on its application mainly based in ethical issues and safety. While safety is thoroughly checked through carefully selected donors and strict microbiological control techniques, international consensus is not effective, yet because of the ethical, logistical, and technical issues (183,184). Clostridium difficile infectious diarrhea was alleviated successfully following FMT (185).…”

Section: Therapeutic Approachesmentioning

confidence: 99%

“…Last but not least, we state here the modulation of the intestinal microbiota following kidney transplantation (183,190).…”

Section: Therapeutic Approachesmentioning

confidence: 99%

See 2 more Smart Citations

Focus on the Gut–Kidney Axis in Health and Disease

et al. 2021

View full text Add to dashboard Cite

The recent new developments in technology with culture-independent techniques including genome sequencing methodologies shed light on the identification of microbiota bacterial species and their role in health and disease. Microbiome is actually reported as an important predictive tool for evaluating characteristic shifts in case of disease. Our present review states the development of different renal diseases and pathologies linked to the intestinal dysbiosis, which impacts on host homeostasis. The gastrointestinal–kidney dialogue provides intriguing features in the pathogenesis of several renal diseases. Without any doubt, investigation of this interconnection consists one of the most cutting-edge areas of research with potential implications on our health.

show abstract

Section: Therapeutic Approachesmentioning

confidence: 99%

Section: Therapeutic Approachesmentioning

confidence: 99%

See 1 more Smart Citation

Focus on the Gut–Kidney Axis in Health and Disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Fever and elevations in inflammatory markers have been observed in patients with IBD following FMT [Rubin, 2013]. Despite screening measures, there are also concerns that FMT may transmit infectious agents that may not manifest in disease for years [Bourlioux and Workgroup of the French Academy of Pharmacy, 2015]. To help mitigate this risk, several groups are evaluating the role of a rationally designed ‘artificial stool’ that contains a subset of clinically active microbes with more limited infectious risks [Petrof et al 2013; Petrof and Khoruts, 2014].…”

Section: Microbiota-based Therapiesmentioning

confidence: 99%

The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions

Vindigni

Zisman

Suskind

et al. 2016

Therap Adv Gastroenterol

170

118

View full text Add to dashboard Cite

We discuss the tripartite pathophysiological circuit of inflammatory bowel disease (IBD), involving the intestinal microbiota, barrier function, and immune system. Dysfunction in each of these physiological components (dysbiosis, leaky gut, and inflammation) contributes in a mutually interdependent manner to IBD onset and exacerbation. Genetic and environmental risk factors lead to disruption of gut homeostasis: genetic risks predominantly affect the immune system, environmental risks predominantly affect the microbiota, and both affect barrier function. Multiple genetic and environmental 'hits' are likely necessary to establish and exacerbate disease. Most conventional IBD therapies currently target only one component of the pathophysiological circuit, inflammation; however, many patients with IBD do not respond to immune-modulating therapies. Hope lies in new classes of therapies that target the microbiota and barrier function.

show abstract

Clostridium Difficile

Sharma¹

2023

Basics of Hematopoietic Stem Cell Transplant

View full text Add to dashboard Cite

Faecal microbiota transplantation: Key points to consider

Cited by 9 publications

References 46 publications

Focus on the Gut–Kidney Axis in Health and Disease

Focus on the Gut–Kidney Axis in Health and Disease

The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions

Clostridium Difficile

Contact Info

Product

Resources

About